Short Interest in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Drops By 33.8%

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) was the recipient of a large decrease in short interest in the month of October. As of October 31st, there was short interest totalling 109,800 shares, a decrease of 33.8% from the October 15th total of 165,900 shares. Based on an average trading volume of 65,200 shares, the short-interest ratio is presently 1.7 days. Approximately 2.3% of the shares of the company are short sold.

Brainstorm Cell Therapeutics Stock Performance

Shares of Brainstorm Cell Therapeutics stock opened at $1.21 on Friday. The stock has a market capitalization of $6.44 million, a P/E ratio of -0.35 and a beta of 0.40. Brainstorm Cell Therapeutics has a 52-week low of $1.05 and a 52-week high of $11.89. The stock’s 50-day simple moving average is $2.53 and its 200 day simple moving average is $4.71.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last posted its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported ($0.60) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.60). During the same quarter in the prior year, the business posted ($4.05) earnings per share. Equities research analysts forecast that Brainstorm Cell Therapeutics will post -2.85 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, StockNews.com downgraded Brainstorm Cell Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Brainstorm Cell Therapeutics stock. Armistice Capital LLC purchased a new stake in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 7,917,653 shares of the biotechnology company’s stock, valued at approximately $2,680,000. Armistice Capital LLC owned approximately 11.30% of Brainstorm Cell Therapeutics as of its most recent filing with the Securities & Exchange Commission. 14.33% of the stock is owned by institutional investors.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.